Open access
Aug 2026
Ibrutinib-triggered matriptase maintains extracellular CD19 and limits antigen escape in B-cell malignancy
CD19-directed CART therapy has improved outcomes in B-cell malignancies, but durable responses remain limited by antigen escape, in which loss of surface CD19 can drive antigen-negative relapse. Ibrutinib (IB) has been reported to enhance CART activity, yet whether IB directly modulates tumor-cell antigen presentatio...
Xin-Jie Lu, Hsing-Fan Lai, Yu-Sin Hung et al.
· Cell Death Discovery · 0 citations